JP2005533835A5 - - Google Patents

Download PDF

Info

Publication number
JP2005533835A5
JP2005533835A5 JP2004520132A JP2004520132A JP2005533835A5 JP 2005533835 A5 JP2005533835 A5 JP 2005533835A5 JP 2004520132 A JP2004520132 A JP 2004520132A JP 2004520132 A JP2004520132 A JP 2004520132A JP 2005533835 A5 JP2005533835 A5 JP 2005533835A5
Authority
JP
Japan
Prior art keywords
compound
alkyl
aryl
pharmaceutical composition
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2004520132A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005533835A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2003/021700 external-priority patent/WO2004005277A1/en
Publication of JP2005533835A publication Critical patent/JP2005533835A/ja
Publication of JP2005533835A5 publication Critical patent/JP2005533835A5/ja
Pending legal-status Critical Current

Links

JP2004520132A 2002-07-09 2003-07-09 新規の化合物、それを含有する医薬組成物、およびその使用方法 Pending JP2005533835A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39458502P 2002-07-09 2002-07-09
PCT/US2003/021700 WO2004005277A1 (en) 2002-07-09 2003-07-09 Novel compunds, pharmaceutical compositions containing same, and methods of use for same

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2010228956A Division JP2011037881A (ja) 2002-07-09 2010-10-08 新規の化合物、それを含有する医薬組成物、およびその使用方法

Publications (2)

Publication Number Publication Date
JP2005533835A JP2005533835A (ja) 2005-11-10
JP2005533835A5 true JP2005533835A5 (https=) 2007-10-04

Family

ID=30115739

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2004520132A Pending JP2005533835A (ja) 2002-07-09 2003-07-09 新規の化合物、それを含有する医薬組成物、およびその使用方法
JP2010228956A Pending JP2011037881A (ja) 2002-07-09 2010-10-08 新規の化合物、それを含有する医薬組成物、およびその使用方法
JP2013117677A Pending JP2013189464A (ja) 2002-07-09 2013-06-04 新規の化合物、それを含有する医薬組成物、およびその使用方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2010228956A Pending JP2011037881A (ja) 2002-07-09 2010-10-08 新規の化合物、それを含有する医薬組成物、およびその使用方法
JP2013117677A Pending JP2013189464A (ja) 2002-07-09 2013-06-04 新規の化合物、それを含有する医薬組成物、およびその使用方法

Country Status (13)

Country Link
US (2) US7649012B2 (https=)
EP (3) EP2386550A1 (https=)
JP (3) JP2005533835A (https=)
KR (1) KR101087559B1 (https=)
CN (2) CN100513404C (https=)
AU (1) AU2003265267B2 (https=)
BR (1) BRPI0312649A2 (https=)
CA (2) CA2491802C (https=)
EA (1) EA013371B1 (https=)
IL (2) IL166108A0 (https=)
MX (1) MXPA05000365A (https=)
SG (1) SG169236A1 (https=)
WO (1) WO2004005277A1 (https=)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2474884A1 (en) 2002-02-08 2003-08-14 John Hopkins University School Of Medicine Stimulation of cpt-1 as a means to reduce weight
BRPI0312654A2 (pt) * 2002-07-09 2017-05-02 Fasgen Llc métodos de tratar infecções microbianas em seres humanos e animais
EA013371B1 (ru) * 2002-07-09 2010-04-30 Фасджен, Ллс. Новые соединения, содержащие их фармацевтические композиции и способы их применения
MXPA06013687A (es) * 2004-05-26 2007-10-18 Fasgen Llc Compuestos novedosos, composiciones farmaceuticas que los contienen y metodos para utilizar los mismos.
EP2061767B1 (de) 2006-08-08 2014-12-17 Sanofi Arylaminoaryl-alkyl-substituierte Imidazolidin-2,4-dione, Verfahren zu ihrer Herstellung, diese Verbindungen enthaltende Arzneimittel und ihre Verwendung
MX2009004950A (es) * 2006-11-08 2009-07-27 Fasgen Llc Nuevos compuestos, composiciones farmaceuticas que contienen los mismos, y metodos de uso de los mismos.
WO2008059214A1 (en) * 2006-11-13 2008-05-22 Astrazeneca Ab Bisamlde derivatives and use thereof as fatty acid synthase inhibitors
EP2285215A4 (en) * 2008-06-02 2012-04-04 Fasgen Inc NOVEL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREFOR AND METHOD OF USE THEREOF
UY31968A (es) 2008-07-09 2010-01-29 Sanofi Aventis Nuevos derivados heterocíclicos, sus procesos para su preparación, y sus usos terapéuticos
WO2010068601A1 (en) 2008-12-08 2010-06-17 Sanofi-Aventis A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
US8729239B2 (en) 2009-04-09 2014-05-20 Nuclea Biotechnologies, Inc. Antibodies against fatty acid synthase
US9149445B2 (en) 2009-07-27 2015-10-06 The Trustees Of Princeton University Inhibition of glycerol-3-phosphate acyltransferase (GPAT) and associated enzymes for treatment of viral infections
KR20120060207A (ko) 2009-08-26 2012-06-11 사노피 신규한 결정성 헤테로방향족 플루오로글리코시드 수화물, 이들 화합물을 포함하는 약제 및 이들의 용도
CA2798330A1 (en) 2010-05-05 2011-11-10 Infinity Pharmaceuticals, Inc. Tetrazolones as inhibitors of fatty acid synthase
US8450350B2 (en) 2010-05-05 2013-05-28 Infinity Pharmaceuticals, Inc. Triazoles as inhibitors of fatty acid synthase
WO2012120058A1 (de) 2011-03-08 2012-09-13 Sanofi Mit benzyl- oder heteromethylengruppen substituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120051A1 (de) 2011-03-08 2012-09-13 Sanofi Mit adamantan- oder noradamantan substituierte benzyl-oxathiazinderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2683699B1 (de) 2011-03-08 2015-06-24 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120056A1 (de) 2011-03-08 2012-09-13 Sanofi Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2683702B1 (de) 2011-03-08 2014-12-24 Sanofi Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
US8895547B2 (en) 2011-03-08 2014-11-25 Sanofi Substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof
US8828994B2 (en) 2011-03-08 2014-09-09 Sanofi Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
EP2766349B1 (de) 2011-03-08 2016-06-01 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2683704B1 (de) 2011-03-08 2014-12-17 Sanofi Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012135027A2 (en) * 2011-03-25 2012-10-04 The Research Foundation Of State University Of New York Thiolactone antibiotics
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
AU2013280980B2 (en) 2012-06-25 2017-10-19 Thomas Jefferson University Compositions and methods for treating cancer with aberrant lipogenic signaling
JP6285442B2 (ja) * 2012-09-07 2018-02-28 ヤンセン ファーマシューティカ エヌ.ベー. がん治療用の脂肪酸合成酵素(fasn)阻害剤として有用なイミダゾリン−5−オン誘導体
ES2753386T3 (es) 2013-03-13 2020-04-08 Forma Therapeutics Inc Derivados de 2-hidroxi-1-{4-[(4-fenil)fenil]carbonil}piperazin-1-il}etano-1-ona y compuestos relacionados como inhibidores de sintasa de ácido graso (FASN) para el tratamiento del cáncer
WO2016079317A1 (en) 2014-11-20 2016-05-26 Vib Vzw Means and methods for treatment of early-onset parkinson's disease
US10793554B2 (en) 2018-10-29 2020-10-06 Forma Therapeutics, Inc. Solid forms of 4-(2-fluoro-4-(1-methyl-1H-benzo[d]imidazol-5-yl)benzoyl)piperazin-1-yl)(1-hydroxycyclopropyl)methanone
CN114480521B (zh) * 2020-11-13 2024-07-26 中国科学院青岛生物能源与过程研究所 一种三氮菌素c的制备方法

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3496187A (en) * 1967-03-20 1970-02-17 American Home Prod N-(heterocyclyl)aconamides
US3472878A (en) * 1969-01-27 1969-10-14 American Home Prod N-(hydroxyaryl)aconamides
JPS5859920A (ja) 1981-10-05 1983-04-09 Chugai Pharmaceut Co Ltd 生体防禦能賦活剤
US4565699A (en) * 1983-07-18 1986-01-21 The Upjohn Company Composition of matter and process
US4720503A (en) * 1985-08-02 1988-01-19 Merck & Co., Inc. N-substituted fused-heterocyclic carboxamide derivatives as dual cyclooxygenase and lipoxygenase inhibitors
CH667655A5 (de) * 1986-09-24 1988-10-31 Lonza Ag Verfahren zur herstellung von 4-alkoxy-2(5h)-thiophenonen.
US4753871A (en) * 1986-12-12 1988-06-28 Eastman Kodak Company Cyan dye-forming couplers and photographic materials containing same
AU1044088A (en) * 1986-12-17 1988-07-15 Nippon Soda Co., Ltd. Heterocyclic compounds having triketo skeleton
US5759837A (en) 1989-01-17 1998-06-02 John Hopkins University Chemotherapy for cancer by inhibiting the fatty acid biosynthetic pathway
US5665874A (en) * 1989-01-17 1997-09-09 John Hopkins University Cancer related antigen
US5759791A (en) * 1989-01-17 1998-06-02 The Johns Hopkins University Cancer related antigen
US5679801A (en) * 1991-04-12 1997-10-21 American Home Products Corporation Tetronic and thiotetronic acid derivatives as phospholipase A2 inhibitors
US5614551A (en) 1994-01-24 1997-03-25 The Johns Hopkins University Inhibitors of fatty acid synthesis as antimicrobial agents
AU5762696A (en) * 1995-05-09 1996-11-29 Bayer Aktiengesellschaft Alkyl dihalogenated phenyl-substituted ketoenols useful as p esticides and herbicides
US5981575A (en) 1996-11-15 1999-11-09 Johns Hopkins University, The Inhibition of fatty acid synthase as a means to reduce adipocyte mass
JPH10212284A (ja) * 1996-11-27 1998-08-11 Sagami Chem Res Center テトロン酸−3−カルボン酸誘導体、その製造方法、製造中間体、抗がん剤、及び蛋白脱リン酸化酵素阻害剤
US6391912B1 (en) * 1996-12-12 2002-05-21 Bayer Aktiengesellschaft Substituted phenylketoenols
CO4970714A1 (es) * 1997-09-05 2000-11-07 Boehringer Mannheim Gmbh Derivados ureido y tioureido de 4-amino-2(5h)-furanonas y 4-amino-2(5h) tiofenonas como agentes antitumorales
HN2000000051A (es) * 1999-05-19 2001-02-02 Pfizer Prod Inc Derivados heterociclicos utiles como agentes anticancerosos
IT1315267B1 (it) * 1999-12-23 2003-02-03 Novuspharma Spa Derivati di 2-(1h-indol-3-il)-2-oxo-acetammidi ad attivita'antitumorale
GB0000131D0 (en) * 2000-01-06 2000-02-23 Univ Cardiff Thiolactomycin analogues,compositions containing the same and uses thereof
US6376682B1 (en) * 2000-02-01 2002-04-23 Takama System, Ltd. Compound with α-glucosidase inhibiting action and method for producing the same
MY134040A (en) 2001-05-02 2007-11-30 Univ New York Inhibition of pigmentation by inhibition of fatty acid synthase
CA2474884A1 (en) * 2002-02-08 2003-08-14 John Hopkins University School Of Medicine Stimulation of cpt-1 as a means to reduce weight
BRPI0312654A2 (pt) 2002-07-09 2017-05-02 Fasgen Llc métodos de tratar infecções microbianas em seres humanos e animais
EA013371B1 (ru) * 2002-07-09 2010-04-30 Фасджен, Ллс. Новые соединения, содержащие их фармацевтические композиции и способы их применения
US9690894B1 (en) 2015-11-02 2017-06-27 Altera Corporation Safety features for high level design

Similar Documents

Publication Publication Date Title
JP2005533835A5 (https=)
JP2002539181A5 (https=)
JP2010530881A5 (https=)
JP2009504763A5 (https=)
RU2003116059A (ru) Арилэфирзамещенные имидазохинолины
JP2005511592A5 (https=)
JP2007523185A5 (https=)
JP2007191486A5 (https=)
RU2000132188A (ru) Производные эпотилонов, их синтез и применение
JP2004520292A5 (https=)
JP2002520416A5 (https=)
JP2002539159A5 (https=)
JP2020075939A5 (https=)
JP2005536553A5 (https=)
JP2010515731A5 (https=)
JP2006507220A5 (https=)
JP2002539156A5 (https=)
JP2005526836A5 (https=)
JP2001526218A5 (https=)
JP2007507494A5 (https=)
JP2012508251A5 (https=)
JP2005517677A5 (https=)
JP2021522327A5 (https=)
RU2005121908A (ru) Производные зн-хиназолин-4-она
RU2003134629A (ru) Соединения цефема